glp 1 cardiac benefits The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 Receptor - Mousai Wellness
Description
Shchendrygina A, Rakisheva A, Giverts I, Rustamova Y, Soloveva A
The American Diabetes Association (ADA) guidelines recommend specific GLP-1 agonists with proven cardiovascular benefit (such as liraglutide, injectable semaglutide, and dulaglutide) for patients with type 2 diabetes and established atherosclerotic cardiovascular disease
Recent studies have indicated that GLP-1RAs may possess neuroprotective properties (12) and directly reduce ICP
It's been open to the public since 2016
The presence of GLP-1 receptors in the central nervous system, particularly in the ventral tegmental area (VTA) and nucleus accumbens (NAc), suggests their involvement in reward processing and motivation
